DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
65.49
+0.24 (0.37%)
At close: Dec 5, 2025, 4:00 PM EST
65.70
+0.21 (0.32%)
After-hours: Dec 5, 2025, 7:02 PM EST
DexCom Revenue
DexCom had revenue of $1.21B in the quarter ending September 30, 2025, with 21.64% growth. This brings the company's revenue in the last twelve months to $4.52B, up 14.21% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.52B
Revenue Growth
+14.21%
P/S Ratio
5.67
Revenue / Employee
$438,437
Employees
10,300
Market Cap
25.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DXCM News
- 17 hours ago - HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 1 day ago - Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights Before Upcoming Deadlines - GlobeNewsWire
- 2 days ago - Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy - Business Wire
- 9 days ago - Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review - Seeking Alpha
- 10 days ago - Touchstone Sands Capital Select Growth Fund Q3 Contributors And Detractors - Seeking Alpha
- 10 days ago - Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights - GlobeNewsWire
- 10 days ago - GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - Newsfile Corp
- 11 days ago - Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc. - PRNewsWire